bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Authors: Rimkunas Victoria M. , Crosby Katherine E. , Li Daiqiang , Hu Yerong , Kelly Meghan E. , Gu Ting-Lei , Mack Jennifer S. , Silver Matthew R. , Zhou Xinmin , Haack Herbert
Published: April 2023

PDF file, 3170KB, (A) Schematic representation of the genomic region containing fig and ros1. Probes set 1 derived from ros1 (orange) and the deleted region (green). Probe set 2 derived from ros1 (orange) and fig (green). (B,C) Yellow arrows point to split signals indicative of balanced translocation in the HCC78 cell line and white arrows point to intact chromosome. (D,F) In both U-118 MG and tumor ID 749 only the ros1 (orange) probe anneals and the deleted region (green probe) does not. (E,G) ros1 (orange) and fig (green) probes overlap indicating fig-ros1 fusion. (H)
Supplementary Table 1 from Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma
Authors: Sugimura Keijiro , Miyata Hiroshi , Tanaka Koji , Hamano Rie , Takahashi Tsuyoshi , Kurokawa Yukinori , Yamasaki Makoto , Nakajima Kiyokazu , Takiguchi Shuji , Mori Masaki , Doki Yuichiro
Published: April 2023

PDF file, 58K, Characteristics of participating patients (n=98).
Analysis of ALK and EGFR L858R expression in tumor ID 664 from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Authors: Rimkunas Victoria M. , Crosby Katherine E. , Li Daiqiang , Hu Yerong , Kelly Meghan E. , Gu Ting-Lei , Mack Jennifer S. , Silver Matthew R. , Zhou Xinmin , Haack Herbert
Published: April 2023

(A) A representative image of ALK break apart FISH (yellow arrows point to break apart). Images of ALK /L858R positive lung adenocarcinoma stained with (B) ALK D5F3, (C) total EGFR, (D) EGFR A746-E750del and (E) EGFR L858R antibodies.
Supplementary Tables 1 - 3 from Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Authors: Fox Elizabeth , Widemann Brigitte C. , Chuk Meredith K. , Marcus Leigh , Aikin Alberta , Whitcomb Patricia O. , Merino Maria J. , Lodish Maya , Dombi Eva , Steinberg Seth M. , Wells Samuel A. , Balis Frank M.
Published: April 2023

PDF file - 118K, Supplemental Data Table 1: Additional Eligibility Criteria. Supplemental Table 2: Drugs that are generally accepted as having a risk of causing Torsades de Pointes and were restricted during enrollment on this clinical trial. Supplemental Table 3: Schedule of Required Evaluations.
Supplementary Figure 3 from IL-17–Mediated M1/M2 Macrophage Alteration Contributes to Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws
Authors: Zhang Qunzhou , Atsuta Ikiru , Liu Shiyu , Chen Chider , Shi Shihong , Shi Songtao , Le Anh D.
Published: April 2023

PDF file - 97K, Jaw bone marrows of mice exhibit elevated level of Th-17/IL-17 than long bone marrows.
Supplementary Figure 2 from IL-17–Mediated M1/M2 Macrophage Alteration Contributes to Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws
Authors: Zhang Qunzhou , Atsuta Ikiru , Liu Shiyu , Chen Chider , Shi Shihong , Shi Songtao , Le Anh D.
Published: April 2023

PDF file - 72K, Systemic infusion of human serum from BRONJ patients promotes BRONJ-like lesion development in C57BL/6 mice.
Supplementary Methods, Figures 1-7, Tables 1-2 from STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following c-Src Inhibition in Head and Neck Squamous Carcinoma
Authors: Sen Banibrata , Peng Shaohua , Woods Denise M. , Wistuba Ignacio , Bell Diana , El-Naggar Adel K. , Lai Stephen Y. , Johnson Faye M.
Published: April 2023

PDF file - 775K
Supplementary Table 1 from Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression
Authors: Schwarzenbach Heidi , Eichelser Corinna , Kropidlowski Jolanthe , Janni Wolfgang , Rack Brigitte , Pantel Klaus
Published: April 2023

PDF file, 54K, Table S1. Comparison of the LOH incidences at each marker in both fractions.
Supplementary Figure Legend from Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model
Authors: van der Bilt Arne R.M. , van Scheltinga Anton G.T. Terwisscha , Timmer-Bosscha Hetty , Schröder Carolien P. , Pot Linda , Kosterink Jos G.W. , van der Zee Ate G.J. , Lub-de Hooge Marjolijn N. , de Jong Steven , de Vries Elisabeth G.E. , Reyners Anna K.L.
Published: April 2023

PDF file - 46K
Supplementary Figure Legend from Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression
Authors: Schwarzenbach Heidi , Eichelser Corinna , Kropidlowski Jolanthe , Janni Wolfgang , Rack Brigitte , Pantel Klaus
Published: April 2023

PDF file, 44K.
Supplementary Tables 1 - 4 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
Authors: Blatt Katharina , Herrmann Harald , Hoermann Gregor , Willmann Michael , Cerny-Reiterer Sabine , Sadovnik Irina , Herndlhofer Susanne , Streubel Berthold , Rabitsch Werner , Sperr Wolfgang R. , Mayerhofer Matthias , Rülicke Thomas , Valent Peter
Published: April 2023

PDF file - 85K, Supplementary Table S1: Characteristics of patients with MDS Supplementary Table S2: Characteristics of patients with AML Supplementary Table S3: Characteristics of patients with CML, CMML, MPS, AUL, and ALL Supplementary Table S4: Characteristics of patients with ICUS, normal/reactive bone marrow and long-term complete remission.
Supplementary Table 5 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
Authors: Blatt Katharina , Herrmann Harald , Hoermann Gregor , Willmann Michael , Cerny-Reiterer Sabine , Sadovnik Irina , Herndlhofer Susanne , Streubel Berthold , Rabitsch Werner , Sperr Wolfgang R. , Mayerhofer Matthias , Rülicke Thomas , Valent Peter
Published: April 2023

PDF file - 48K, Supplementary Table S5: The oligonucleotide primer sequences for quantitative PCR (qPCR).
Supplementary Figure S1 from The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis
Authors: Luscan Armelle , Shackleford Ghjuvan'Ghjacumu , Masliah-Planchon Julien , Laurendeau Ingrid , Ortonne Nicolas , Varin Jennifer , Lallemand François , Leroy Karen , Dumaine Valérie , Hivelin Mikael , Borderie Didier , De Raedt Thomas , Valeyrie-Allanore Laurence , Larousserie Frédérique , Terris Benoît , Lantieri Laurent , Vidaud Michel , Vidaud Dominique , Wolkenstein Pierre , Parfait Béatrice , Bièche Ivan , Massaad Charbel , Pasmant Eric
Published: April 2023

PDF file 161K, A simplified representation of the three different Wnt signalling pathways: the canonical pathway, the planar cell polarity pathway, and the Wnt/calcium pathway. In the absence of Wnt ligand, the 'destruction complex' composed of the core proteins Axin, adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK3) rapidly phosphorylates cytosolic beta-catenin, targeting it for subsequent proteasome-mediated destruction. Binding of Wnt to Frizzled (FZD) and low-density lipoprotein receptor-related protein 5/6 (LRP5/6) activates the cytosolic protein Dishevelled (DVL), leading to inhibition of the destruction complex. The resulting accumulated beta-catenin can then translocate to the nucleus to activate Wnt-responsive target genes regulated by lymphoid enhancer factor (LEF) and T cell factor (TCF) family transcription factors, leading to various cellular effects. The secreted inhibitor Dickkopf (DKK) can antagonize Wnt signalling by competitively binding to LRP5/6. Secreted FZD-related proteins (SFRPs) and Wnt inhibitory factor (WIF) are thought to antagonize Wnt signalling by sequestering Wnt ligand in the extracellular space. Binding of Wnt isoforms to FZD can trigger beta-catenin-independent downstream signalling events, other so-called non-canonical Wnt pathways that do not require the transcriptional activity of beta-catenin. One branch of non-canonical pathways involves the activation of RHO and RAC small G proteins to regulate the actin cytoskeleton. DVL-associated activator of morphogenesis 1 (DAAM1), when complexed with DVL and RHO, acts through the regulation of RHO-associated protein kinases (ROCK) and the DVL-RAC GTPase complex to affect actin remodelling. Another branch, when activated, is defined by a phospholipase C (PLC)-mediated increase in intracellular Ca2+ levels and Ca2+ fluxes that lead to the activation of Ca2+/calmodulin-dependent protein kinase (CaMK), protein kinase C (PKC), and nuclear factor of activated T cells (NFAT)
Supplementary Figure 6 from Downregulation of miR-138 Sustains NF-κB Activation and Promotes Lipid Raft Formation in Esophageal Squamous Cell Carcinoma
Authors: Gong Hui , Song Libing , Lin Chuyong , Liu Aibin , Lin Xi , Wu Jueheng , Li Mengfeng , Li Jun
Published: April 2023

PDF file - 51 KB, Silencing miR-138 sustains NF-�B activity.
Supplementary Figure 2 from Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Authors: John Liza B. , Devaud Christel , Duong Connie P.M. , Yong Carmen S. , Beavis Paul A. , Haynes Nicole M. , Chow Melvyn T. , Smyth Mark J. , Kershaw Michael H. , Darcy Phillip K.
Published: April 2023

Supplementary Figure 2 - PDF file 20K, Expression of PD-1 is upregulated on CAR T cells following antigen stimulation with e0771-Her2+ tumor cells
Supplementary Tables 1 - 2, Figure 1 - 11 from Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Authors: Polański Radosław , Hodgkinson Cassandra L. , Fusi Alberto , Nonaka Daisuke , Priest Lynsey , Kelly Paul , Trapani Francesca , Bishop Paul W. , White Anne , Critchlow Susan E. , Smith Paul D. , Blackhall Fiona , Dive Caroline , Morrow Christopher J.
Published: April 2023

PDF file - 1117K, Supplemental Table 1 - p53, RB and Myc status of the SCLC cell line panel investigated. Supplemental Table 2 - Characteristics of SCLC patients represented in the TMA. Supplemental Figure 1 - Structure of AZD3965. Supplemental Figure 2 - Effect of MCT1 overexpression on AZD3965 sensitivity in NCI-H1048 cells. Supplemental Figure 3 - Representative cell cycle profiles of normoxic and hypoxic SCLC cell lines treated with AZD3965. Supplemental Figure 4 - The effect of AZD3965 treatment on autophagy assessed by LC3 western blotting. Supplemental Figure 5 - Correlation between hypoxic MCT4 expression and AZD3965 sensitivity. Supplemental Figure 6 - MCT1 and MCT4 IHC of COR-L103 xenografts. Supplemental Figure 7 - Validation of MCT1 and MCT4 IHC staining. Supplemental Figure 8 - Representative images of MCT1, MCT4 and CA IX IHC staining in the SCLC TMA. Supplemental Figure 9 - Inter-scorer correlation of MCT1, MCT4 and CA IX TMA staining and distribution of MCT1, MCT4 and CA IX staining score across the TMA. Supplemental Figure 10 - Correlation between MCT4 and CA IX staining in the SCLC TMA. Supplemental Figure 11 - Effect of CA IX expression, stage and serum LDH on SCLC patient survival.
Supplementary Table 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Authors: Coiffier Bertrand , Li Weimin , Henitz Erin D. , Karkera Jayaprakash D. , Favis Reyna , Gaffney Dana , Shapiro Alice , Theocharous Panteli , Elsayed Yusri A. , van de Velde Helgi , Schaffer Michael E. , Osmanov Evgenii A. , Hong Xiaonan , Scheliga Adriana , Mayer Jiri , Offner Fritz , Rule Simon , Teixeira Adriana , Romejko-Jarosinska Joanna , de Vos Sven , Crump Michael , Shpilberg Ofer , Zinzani Pier Luigi , Cakana Andrew , Esseltine Dixie-Lee , Mulligan George , Ricci Deborah
Published: April 2023

Supplementary Table 3 PDF file 70K, Median PFS for patients in the discovery and confirmation sets, and in all patients, in the cross-validation model (see Supplementary Materials) who were positive or negative for the biomarker pair PSMB1 P11A (G allele) and low CD68 expression (≤50 CD68-positive cells). Presence of the biomarker pair was associated with a significant PFS benefit in patients treated with bortezomib-rituximab versus rituximab in the discovery set, a positive trend in the smaller confirmation sets, and a significant benefit among all patients. No significant differences were seen for biomarker-negative patients
Supplementary Table 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Authors: Coiffier Bertrand , Li Weimin , Henitz Erin D. , Karkera Jayaprakash D. , Favis Reyna , Gaffney Dana , Shapiro Alice , Theocharous Panteli , Elsayed Yusri A. , van de Velde Helgi , Schaffer Michael E. , Osmanov Evgenii A. , Hong Xiaonan , Scheliga Adriana , Mayer Jiri , Offner Fritz , Rule Simon , Teixeira Adriana , Romejko-Jarosinska Joanna , de Vos Sven , Crump Michael , Shpilberg Ofer , Zinzani Pier Luigi , Cakana Andrew , Esseltine Dixie-Lee , Mulligan George , Ricci Deborah
Published: April 2023

Supplementary Table 2 PDF file 78K, Evaluation of PFS and OS under the G-dominant genetic model for PSMB1 P11A among all patients evaluable for the biomarker pair of PSMB1 P11A genotype and CD68 expression who had low (≤50 CD68-positive cells) CD68 expression
Fig. S6 from The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α–Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer
Authors: Heckmann Doreen , Maier Patrick , Laufs Stephanie , Li Li , Sleeman Jonathan P. , Trunk Marcus J. , Leupold Jörg H. , Wenz Frederik , Zeller W. Jens , Fruehauf Stefan , Allgayer Heike
Published: April 2023

PDF file 129K, S6: Confirmation of expression of microRNAs and putative target genes in SW480wildtype, SW480CXCR4, SW480CXCR7, and SW480CXCR4/CXCR7 cells treated with SDF-1a for 0, 3 and 12 h by qPCR
Figure S1 from miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression
Authors: Tang Hailin , Deng Min , Tang Yunyun , Xie Xinhua , Guo Jiaoli , Kong Yanan , Ye Feng , Su Qi , Xie Xiaoming
Published: April 2023

Figure S1 - PDF file 1773K, miR-200a expression levels is unchanged in human gastric cancer.(A) The expression levels of miR-200a was detected in 36 gastric cancer patients by qRT-PCR. Data are shown as fold change of gastric cancer relative to adjacent normal tissues. (B) Relative expression of miR-200a in 7 cell lines derived from gastric cancer and one nonmalignant gastric cell line (GES-1) was determined by qRT-PCR. Data are presented as mean � SD from at least three separate experiments
Supplementary Figure 3 from Frequent Overexpression of HMGA2 in Human Atypical Teratoid/Rhabdoid Tumor and Its Correlation with let-7a3/let-7b miRNA
Authors: Zhang Keqiang , Gao Hanlin , Wu Xiwei , Wang Jinhui , Zhou Wendi , Sun Guihua , Wang Jinghan , Wang Yafan , Mu Bing , Kim Charles , Chu Peiguo , Ho Donald M. , Ann David K. , Wong Tai-Tong , Yen Yun
Published: April 2023

PDF file - 3492K, Figure S3. Sanger DNA-sequencing for AT/RT tissue specific point mutations including DBF4 (c.794C>G, p.T265S); PMS1 (c.2524C>A, p.L842I); RASSF4 (c.494A>C, p.H165P); Rap2b (c.240G>C, p.L80I); and Tie2 (c.1249C>A, p.P417T) genes. The upper panel for sequencing of genomic DNA extracted from saliva, the lower panel for AT/RT.
Supplementary Figure Legend from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
Authors: Escudier Bernard , Grünwald Viktor , Ravaud Alain , Ou Yen-Chuan , Castellano Daniel , Lin Chia-Chi , Gschwend Jürgen E. , Harzstark Andrea , Beall Sarah , Pirotta Nicoletta , Squires Matthew , Shi Michael , Angevin Eric
Published: April 2023

PDF file - 20KB
Supplementary Tables 1- 3 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Authors: Phillips Gail D. Lewis , Fields Carter T. , Li Guangmin , Dowbenko Donald , Schaefer Gabriele , Miller Kathy , Andre Fabrice , Burris Howard A. , Albain Kathy S. , Harbeck Nadia , Dieras Veronique , Crivellari Diana , Fang Liang , Guardino Ellie , Olsen Steven R. , Crocker Lisa M. , Sliwkowski Mark X.
Published: April 2023

PDF file 288K, Supp. Table 1: TDM4373g Patient Demographics and Baseline Characteristics; Supp. Table 2: TDM4373g Prior Therapies; Supp. Table 3: TDM4373g Adverse Events
Supplementary Methods from Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers
Authors: Di Caro Giuseppe , Bergomas Francesca , Grizzi Fabio , Doni Andrea , Bianchi Paolo , Malesci Alberto , Laghi Luigi , Allavena Paola , Mantovani Alberto , Marchesi Federica
Published: April 2023

PDF file - 58K
Supplementary Table S2 from Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer
Authors: Janssens Geert O. , Rademakers Saskia E. , Terhaard Chris H. , Doornaert Patricia A. , Bijl Hendrik P. , van den Ende Piet , Chin Alim , Takes Robert P. , de Bree Remco , Hoogsteen Ilse J. , Bussink Johan , Span Paul N. , Kaanders Johannes H.
Published: April 2023

Table S2. Eligibility criteria.
Supplementary Figure S4 from GKN1–miR-185–DNMT1 Axis Suppresses Gastric Carcinogenesis through Regulation of Epigenetic Alteration and Cell Cycle
Authors: Yoon Jung Hwan , Choi Yoo Jin , Choi Won Suk , Ashktorab Hassan , Smoot Duane T. , Nam Suk Woo , Lee Jung Young , Park Won Sang
Published: April 2023

Supplementary Figure S4 - PDF file 1562K, Effects of DNMT1, ESZH2 and HDAC1 silencing in AGS cells
Supplementary Table 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Authors: Gucalp Ayca , Tolaney Sara , Isakoff Steven J. , Ingle James N. , Liu Minetta C. , Carey Lisa A. , Blackwell Kimberly , Rugo Hope , Nabell Lisle , Forero Andres , Stearns Vered , Doane Ashley S. , Danso Michael , Moynahan Mary Ellen , Momen Lamia F. , Gonzalez Joseph M. , Akhtar Arooj , Giri Dilip D. , Patil Sujata , Feigin Kimberly N. , Hudis Clifford A. , Traina Tiffany A.
Published: April 2023

Supplementary Table 1 - PDF file 4K, Supplementary Table 1. Median hormone levels at baseline, start of cycle 2 (C2), and end of study (EOS) and the percent change in levels from baseline to C2 and C2 to EOS
Supplementary Figure S3 from GKN1–miR-185–DNMT1 Axis Suppresses Gastric Carcinogenesis through Regulation of Epigenetic Alteration and Cell Cycle
Authors: Yoon Jung Hwan , Choi Yoo Jin , Choi Won Suk , Ashktorab Hassan , Smoot Duane T. , Nam Suk Woo , Lee Jung Young , Park Won Sang
Published: April 2023

Supplementary Figure S3 - PDF file 860K, Effects of GKN1 on expression of DNMT1 and EZH2 in MKN1 and MKN28
Supplementary Methods from Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
Authors: Garralda Elena , Paz Keren , López-Casas Pedro P. , Jones Siân , Katz Amanda , Kann Lisa M. , López-Rios Fernando , Sarno Francesca , Al-Shahrour Fátima , Vasquez David , Bruckheimer Elizabeth , Angiuoli Samuel V. , Calles Antonio , Diaz Luis A. , Velculescu Victor E. , Valencia Alfonso , Sidransky David , Hidalgo Manuel
Published: April 2023

PDF file - 38KB, Protocol for Avatar Generation.
Table S2 from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
Authors: Puchades-Carrasco Leonor , Lecumberri Ramón , Martínez-López Joaquín , Lahuerta Juan-José , Mateos María-Victoria , Prósper Felipe , San-Miguel Jesús F. , Pineda-Lucena Antonio
Published: April 2023

Table S2 - PDF file 93K, Relative amounts of most significant metabolites in the OPLS-DA model from the group of MM patients at the time of diagnosis and after achieving complete remission
Table S1 from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
Authors: Puchades-Carrasco Leonor , Lecumberri Ramón , Martínez-López Joaquín , Lahuerta Juan-José , Mateos María-Victoria , Prósper Felipe , San-Miguel Jesús F. , Pineda-Lucena Antonio
Published: April 2023

Table S1 - PDF file 103K, Relative amounts of most significant metabolites in the OPLS-DA model from the control group and the MM patients at the time of diagnosis
Online Supplement from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
Authors: Puchades-Carrasco Leonor , Lecumberri Ramón , Martínez-López Joaquín , Lahuerta Juan-José , Mateos María-Victoria , Prósper Felipe , San-Miguel Jesús F. , Pineda-Lucena Antonio
Published: April 2023

Online Supplement - PDF file 58K, NMR-based metabolomics
Figure S2 from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
Authors: Puchades-Carrasco Leonor , Lecumberri Ramón , Martínez-López Joaquín , Lahuerta Juan-José , Mateos María-Victoria , Prósper Felipe , San-Miguel Jesús F. , Pineda-Lucena Antonio
Published: April 2023

Figure S2 - PDF file 252K, Box plots in log scale of the metabolites that experienced the most significant variations between the three groups of samples included in the study. Boxes denote 50% of scores, lines denote medians, and whiskers denote the smallest and largest (non-outlier) scores. "o" represent mild outliers (any score more than 1.5xIQR - interquartile range -) and "x" extreme outliers (any score more than 3xIQR). Levels are expressed as area of the metabolite of interest (expressed in arbitrary units; a.u.) divided by 106. (*) Statistically significant differences (p < 0.05)
Supplementary Figure 1 from PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma
Authors: Shigaki Hironobu , Baba Yoshifumi , Watanabe Masayuki , Murata Asuka , Ishimoto Takatsugu , Iwatsuki Masaaki , Iwagami Shiro , Nosho Katsuhiko , Baba Hideo
Published: April 2023

PDF File - 358K, Immunohistochemistry for p-AKT and p53.
Supplementary Table 4 from AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Blayney Jaine K. , Kalimutho Murugan , Greer Samanda , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Loughrey Maurice , Redmond Keara , Longley Daniel B. , Salto-Tellez Manuel , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

PDF file - 165K, Univariate and multivariate analyses in stage II-III CRC group (Singapore dataset) using Cox proportional hazards regression.
Supplementary Table 3 from AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Blayney Jaine K. , Kalimutho Murugan , Greer Samanda , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Loughrey Maurice , Redmond Keara , Longley Daniel B. , Salto-Tellez Manuel , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

PDF file - 189K, Univariate and multivariate analyses in stage I-IV CRC group (Singapore dataset) using Cox proportional hazards regression.
Supplementary Methods from AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Blayney Jaine K. , Kalimutho Murugan , Greer Samanda , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Loughrey Maurice , Redmond Keara , Longley Daniel B. , Salto-Tellez Manuel , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

PDF file - 53K, Statistical analysis.
Supplementary Figure 9 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 116KB, Expression of IL-17A was positively correlated with MMP9 and VEGF.
Supplementary Figure 6 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 903KB, CT-26 cells possess receptors for IL-17A.
Supplementary Figure 5 from Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases
Authors: Tseng Ju-Yu , Yang Chih-Yung , Liang Shu-Ching , Liu Ren-Shyan , Yang Shung-Haur , Lin Jen-Kou , Chen Yuh-Min , Wu Yu-Chung , Jiang Jeng-Kai , Lin Chi-Hung
Published: April 2023

PDF file - 64KB, Treatment with rGM-CSF decreased CTCs and inhibited metastasis.
Supplementary Table 1 from Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients
Authors: Dekervel Jeroen , Hompes Daphne , van Malenstein Hannah , Popovic Dusan , Sagaert Xavier , De Moor Bart , Van Cutsem Eric , D'Hoore André , Verslype Chris , van Pelt Jos
Published: April 2023

PDF file - 86KB, List of genes and RT-PCR assay IDs.
Supplementary Methods from Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology
Authors: Ferté Charles , Trister Andrew D. , Huang Erich , Bot Brian M. , Guinney Justin , Commo Frederic , Sieberts Solveig , André Fabrice , Besse Benjamin , Soria Jean-Charles , Friend Stephen H.
Published: April 2023

PDF file - 81K
Supplementary Figure 1 from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Authors: Mahfouz Reda Z. , Jankowska Ania , Ebrahem Quteba , Gu Xiaorong , Visconte Valeria , Tabarroki Ali , Terse Pramod , Covey Joseph , Chan Kenneth , Ling Yonghua , Engelke Kory J. , Sekeres Mikkael A. , Tiu Ramon , Maciejewski Jaroslaw , Radivoyevitch Tomas , Saunthararajah Yogen
Published: April 2023

PDF file - 297K, Figure S1: CDA mRNA expression in various human tissues. Figure S2: CDA mRNA expression in primary cancer cells. Figure S3: Incidence of MDS in the United States.
Supplementary Figure 1 from Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients
Authors: Dekervel Jeroen , Hompes Daphne , van Malenstein Hannah , Popovic Dusan , Sagaert Xavier , De Moor Bart , Van Cutsem Eric , D'Hoore André , Verslype Chris , van Pelt Jos
Published: April 2023

PDF file - 292KB, Gene expression in cultures of CaCo-2 cells after exposure to hypoxia as determined by RT-qPCR.
Supplementary Methods from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

PDF file - 129K
Supplementary Figure 4 from Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
Authors: Chen Chun-Han , Chen Mei-Chuan , Wang Jing-Chi , Tsai An-Chi , Chen Ching-Shih , Liou Jing-Ping , Pan Shiow-Lin , Teng Che-Ming
Published: April 2023

PDF file - 1056KB, Investigation of the mechanism underlying sorafenibcaused p21 attenuation.
Supplementary Figure 9 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

PDF file - 1995K, Isolation of pancreatic cancer cell line, Panc486.
Supplementary Figure 7 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

PDF file - 116K, In vivo response of xenograftted tumors.
Supplementary Figure 1 from Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
Authors: Chen Chun-Han , Chen Mei-Chuan , Wang Jing-Chi , Tsai An-Chi , Chen Ching-Shih , Liou Jing-Ping , Pan Shiow-Lin , Teng Che-Ming
Published: April 2023

PDF file - 1063KB, Synergistic interaction between MPT0E028 and vorinostat in Hep3B cells.
Supplementary Figure 5 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

PDF file - 105K, Pharmagram of Panc502 to all drugs in the JHDL.
Supplementary Table 1 from First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Authors: Yap Timothy A. , Arkenau Hendrik-Tobias , Camidge D. Ross , George Suzanne , Serkova Natalie J. , Gwyther Stephen J. , Spratlin Jennifer L. , Lal Rohit , Spicer James , Desouza Nandita M. , Leach Martin O. , Chick Jon , Poondru Srinivasu , Boinpally Ramesh , Gedrich Richard , Brock Katie , Stephens Andrew , Eckhardt S. Gail , Kaye Stan B. , Demetri George , Scurr Michelle
Published: April 2023

PDF file - 56K, FDG-PET Responses
Supplementary Figure 1 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Authors: Kamiyama Hirohiko , Rauenzahn Sherri , Shim Joong Sup , Karikari Collins A. , Feldmann Georg , Hua Li , Kamiyama Mihoko , Schuler F. William , Lin Ming-Tseh , Beaty Robert M. , Karanam Balasubramanyam , Liang Hong , Mullendore Michael E. , Mo Guanglan , Hidalgo Manuel , Jaffee Elizabeth , Hruban Ralph H. , Jinnah H.A. , Roden Richard B.S. , Jimeno Antonio , Liu Jun O. , Maitra Anirban , Eshleman James R.
Published: April 2023

PDF file - 79K, Breeding strategy for production and maintenance of the nude hprt-null mouse.
Supplementary Methods from First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Authors: Yap Timothy A. , Arkenau Hendrik-Tobias , Camidge D. Ross , George Suzanne , Serkova Natalie J. , Gwyther Stephen J. , Spratlin Jennifer L. , Lal Rohit , Spicer James , Desouza Nandita M. , Leach Martin O. , Chick Jon , Poondru Srinivasu , Boinpally Ramesh , Gedrich Richard , Brock Katie , Stephens Andrew , Eckhardt S. Gail , Kaye Stan B. , Demetri George , Scurr Michelle
Published: April 2023

PDF file - 86K
Supplementary Figure Legend from First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Authors: Yap Timothy A. , Arkenau Hendrik-Tobias , Camidge D. Ross , George Suzanne , Serkova Natalie J. , Gwyther Stephen J. , Spratlin Jennifer L. , Lal Rohit , Spicer James , Desouza Nandita M. , Leach Martin O. , Chick Jon , Poondru Srinivasu , Boinpally Ramesh , Gedrich Richard , Brock Katie , Stephens Andrew , Eckhardt S. Gail , Kaye Stan B. , Demetri George , Scurr Michelle
Published: April 2023

PDF file - 41K
Supplementary Data from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer
Authors: Etemadmoghadam Dariush , Au-Yeung George , Wall Meaghan , Mitchell Chris , Kansara Maya , Loehrer Elizabeth , Batzios Crisoula , George Joshy , Ftouni Sarah , Weir Barbara A. , Carter Scott , Gresshoff Irma , Mileshkin Linda , Rischin Danny , Hahn William C. , Waring Paul M. , Getz Gad , Cullinane Carleen , Campbell Lynda J. , Bowtell David D.
Published: April 2023

Supplementary Data - PDF file 117K, Microarray analysis of differentially expressed genes in PHA-533533 resistant cell lines
Supplementary Tables 1 - 2, Figure 1 from Adaptive Prediction Model in Prospective Molecular Signature–Based Clinical Studies
Authors: Xiao Guanghua , Ma Shuangge , Minna John , Xie Yang
Published: April 2023

PDF file - 47K, Table S1. Simulation settings, Table S2. Biological verification of genes with high adaptive scores, Figure S1. ROC curves in the simulation study.
Supporting Table 3 from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential
Authors: Qiu Yunping , Cai Guoxiang , Zhou Bingsen , Li Dan , Zhao Aihua , Xie Guoxiang , Li Houkai , Cai Sanjun , Xie Dong , Huang Changzhi , Ge Weiting , Zhou Zhanxiang , Xu Lisa X. , Jia Weiping , Zheng Shu , Yen Yun , Jia Wei
Published: April 2023

PDF file 50K, Treatment information for stage II and stage III patients in Shanghai cohort
Supplementary Figure 4 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
Authors: Proia David A. , Zhang Chaohua , Sequeira Manuel , Jimenez John-Paul , He Suqin , Spector Neil , Shapiro Geoffrey I. , Tolaney Sara , Nagai Masazumi , Acquaviva Jaime , Smith Donald L. , Sang Jim , Bates Richard C. , El-Hariry Iman
Published: April 2023

PDF file - 644K, Gantespib potentiates the efficacy of the microtubule dynamics inhibitor eribulin in TNBC xenografts.
Supporting Table 2 from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential
Authors: Qiu Yunping , Cai Guoxiang , Zhou Bingsen , Li Dan , Zhao Aihua , Xie Guoxiang , Li Houkai , Cai Sanjun , Xie Dong , Huang Changzhi , Ge Weiting , Zhou Zhanxiang , Xu Lisa X. , Jia Weiping , Zheng Shu , Yen Yun , Jia Wei
Published: April 2023

PDF file 66K, Differentially expressed genes between CRC tissue and adjacent normal samples
Supplementary Figure 3 from Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
Authors: Proia David A. , Zhang Chaohua , Sequeira Manuel , Jimenez John-Paul , He Suqin , Spector Neil , Shapiro Geoffrey I. , Tolaney Sara , Nagai Masazumi , Acquaviva Jaime , Smith Donald L. , Sang Jim , Bates Richard C. , El-Hariry Iman
Published: April 2023

PDF file - 2583K, DNA damage and cell cycle distribution following combination ganetespib + doxorubicin treatment.
Supporting Figure 2 from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential
Authors: Qiu Yunping , Cai Guoxiang , Zhou Bingsen , Li Dan , Zhao Aihua , Xie Guoxiang , Li Houkai , Cai Sanjun , Xie Dong , Huang Changzhi , Ge Weiting , Zhou Zhanxiang , Xu Lisa X. , Jia Weiping , Zheng Shu , Yen Yun , Jia Wei
Published: April 2023

PDF file 126K, PCA and OPLS-DA scores plot for CRC samples and adjacent non-tumor tissues collected from Hangzhou, Beijing and City of Hope
Supplementary Table 1 from PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Authors: Walsh Katherine , McKinney Matthew S. , Love Cassandra , Liu Qingquan , Fan Alice , Patel Amee , Smith Jason , Beaven Anne , Jima Dereje D. , Dave Sandeep S.
Published: April 2023

PDF file - 80 KB, Supplementary Table S1 lists the cell lines and their respective IC50s for all three of the PI3K inhibitors evaluated in this study.
Supplementary Figure 1 from PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Authors: Walsh Katherine , McKinney Matthew S. , Love Cassandra , Liu Qingquan , Fan Alice , Patel Amee , Smith Jason , Beaven Anne , Jima Dereje D. , Dave Sandeep S.
Published: April 2023

PDF file - 72 KB, Supplementary Figure S1 shows the results for the experiment to determine if there was a therapeutic window between malignant and normal cells. Both IPA-3 and BEZ235 individually and in combination were selectively toxic to malignant B cells (Ly8 cell line) compared to normal B cells.
Supplementary Table 1 from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Dreicer Robert , MacLean David , Suri Ajit , Stadler Walter M. , Shevrin Daniel , Hart Lowell , MacVicar Gary R. , Hamid Omid , Hainsworth John , Gross Mitchell E. , Shi Yuanjun , Webb Iain J. , Agus David B.
Published: April 2023

PDF file - 65K, Schedule of assessments.
Supplementary Tables 1 - 2 from End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis
Authors: Pyo Junhee , Won Kim Kyung , Jacene Heather A. , Sakellis Christopher G. , Brown Jennifer R. , Van den Abbeele Annick D.
Published: April 2023

PDF file - 144K, Supplementary Table S1. Sensitivity analysis for pooled HR of PET- and CT-based response criteria. Supplementary Table S2. Sensitivity analysis for pooled CR rates and Discordance rates of PET- and CT-based response criteria.
Supplementary Figure Legends, Figures 1 - 4 from Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Authors: Chen Dongshi , Wei Liang , Yu Jian , Zhang Lin
Published: April 2023

PDF file - 301KB, Figure S1. Potential roles of transcription factors in PUMA induction by regorafenib in CRC cells. Figure S2. p65 mediates PUMA induction by regorafenib in CRC cells. Figure S3. PUMA-dependent chemosensitization by regorafenib in CRC cells. Figure S4. PUMA-dependent chemosensitization by regorafenib in xenograft tumors.
Supplementary Figure 1 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
Authors: Furmanski Brian D. , Hu Shuiying , Fujita Ken-ichi , Li Lie , Gibson Alice A. , Janke Laura J. , Williams Richard T. , Schuetz John D. , Sparreboom Alex , Baker Sharyn D.
Published: April 2023

PDF file - 131K, Concentration-dependence of dasatinib transport by ABCC4.
Supplementary Text from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
Authors: Sessa Cristiana , Lorusso Patricia , Tolcher Anthony , Farace Françoise , Lassau Nathalie , Delmonte Angelo , Braghetti Antonio , Bahleda Rastislav , Cohen Patrick , Hospitel Marie , Veyrat-Follet Christine , Soria Jean-Charles
Published: April 2023

Supplementary Text - PDF file 76K, DCE methodology and results
Supplementary Figure 1 from Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease
Authors: Agarwal Amit , Ghobrial Irene M.
Published: April 2023

PDF file - 41K, IMWG recommendations for management of MGUS and Smoldering Myeloma
Supplementary Figure Legend from Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo
Authors: Dakhova Olga , Rowley David , Ittmann Michael
Published: April 2023

PDF file - 49K
Supplementary Figure 1 from Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo
Authors: Dakhova Olga , Rowley David , Ittmann Michael
Published: April 2023

PDF file - 1330K, Western blot with anti-ErbB2 antibody. DRS stromal lines 19I, 19B and 33B (15 ug protein) or LNCaP cells (10 ug protein) were used for Western blotting as described in Materials and Methods. Beta-actin Western blot on the same membrane is a loading control.
Supplementary Table S3 from Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Authors: Pinker Katja , Bogner Wolfgang , Baltzer Pascal , Karanikas Georgios , Magometschnigg Heinrich , Brader Peter , Gruber Stephan , Bickel Hubert , Dubsky Peter , Bago-Horvath Zsuzsanna , Bartsch Rupert , Weber Michael , Trattnig Siegfried , Helbich Thomas H.
Published: April 2023

Detailed histopathological results of false-negative and false-positive lesions.
Supplementary Table S2 from Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Authors: Pinker Katja , Bogner Wolfgang , Baltzer Pascal , Karanikas Georgios , Magometschnigg Heinrich , Brader Peter , Gruber Stephan , Bickel Hubert , Dubsky Peter , Bago-Horvath Zsuzsanna , Bartsch Rupert , Weber Michael , Trattnig Siegfried , Helbich Thomas H.
Published: April 2023

BI-RADSÂ® assessment categories.
Supplementary Figure 6 from Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells
Authors: Yamaguchi Hirohito , Hsu Jennifer L. , Chen Chun-Te , Wang Ying-Nai , Hsu Ming-Chuan , Chang Shih-Shin , Du Yi , Ko How-Wen , Herbst Roy , Hung Mien-Chie
Published: April 2023

PDF file - 38K, The effects of MEK or AKT inhibitor on cisplatin-induced CID
Supplementary Figure S3 from Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Authors: Pinker Katja , Bogner Wolfgang , Baltzer Pascal , Karanikas Georgios , Magometschnigg Heinrich , Brader Peter , Gruber Stephan , Bickel Hubert , Dubsky Peter , Bago-Horvath Zsuzsanna , Bartsch Rupert , Weber Michael , Trattnig Siegfried , Helbich Thomas H.
Published: April 2023

ROC curves illustrate the higher diagnostic accuracy that is reached by MP 18FDG-PET-MRI compared to assessment with a single parameter or with multiparametric MRI with combinations of two/three parameters.
Supplementary Figure 5 from Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells
Authors: Yamaguchi Hirohito , Hsu Jennifer L. , Chen Chun-Te , Wang Ying-Nai , Hsu Ming-Chuan , Chang Shih-Shin , Du Yi , Ko How-Wen , Herbst Roy , Hung Mien-Chie
Published: April 2023

PDF file - 63K, Evaluation of AKT activity by using AKT substrates antibody
Supplementary Figure S2 from Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Authors: Pinker Katja , Bogner Wolfgang , Baltzer Pascal , Karanikas Georgios , Magometschnigg Heinrich , Brader Peter , Gruber Stephan , Bickel Hubert , Dubsky Peter , Bago-Horvath Zsuzsanna , Bartsch Rupert , Weber Michael , Trattnig Siegfried , Helbich Thomas H.
Published: April 2023

Invasive ductal carcinoma G3 in a 67-year-old woman, retroareolar in the right breast [continued from Figure S1]. (A) On 3D 1H-MRSI, the lesion demonstrates elevated Cho levels (SNR 10.23). (B) On 18FDG-PET, the lesion is highly 18FDG-avid, with a maximum SUV of 51.9. (C) This tumor was true-positive according to all techniques, allowing an accurate classification as malignant with MP 18FDG-PET-MRI.
Supplementary Figure 3 from Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells
Authors: Yamaguchi Hirohito , Hsu Jennifer L. , Chen Chun-Te , Wang Ying-Nai , Hsu Ming-Chuan , Chang Shih-Shin , Du Yi , Ko How-Wen , Herbst Roy , Hung Mien-Chie
Published: April 2023

PDF file - 171K, The effects of EGFR TKIs on CID in mt EGFR and wt EGFR cells
Supplementary Figure 1 from Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells
Authors: Yamaguchi Hirohito , Hsu Jennifer L. , Chen Chun-Te , Wang Ying-Nai , Hsu Ming-Chuan , Chang Shih-Shin , Du Yi , Ko How-Wen , Herbst Roy , Hung Mien-Chie
Published: April 2023

PDF file - 53K, The effects of gefitinib or cisplatin on cell growth and cell death
Supplementary Tables 1-3 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Authors: Weekes Colin D. , Von Hoff Daniel D. , Adjei Alex A. , Leffingwell Diane P. , Eckhardt S. Gail , Gore Lia , Lewis Karl D. , Weiss Glen J. , Ramanathan Ramesh K. , Dy Grace K. , Ma Wen W. , Sheedy Beth , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Dubowy Ronald L. , Jeffers Michael , Rajagopalan Prabhu , Clendeninn Neil J.
Published: April 2023

Table S1: Dose-limiting toxicities; Table S2:Multiple-dose pharmacokinetic parameters (geometric mean (%CV) of BAY 86-9766 and metabolite M17 on Course 1, Day 22 (representing exposure after 15 days of continuous dosing) for once-daily dosing cohorts; Table S3: Multiple-dose pharmacokinetic parameters of BAY 86-9766 and metabolite M17 on Course 1, Day 22 (representing exposure after 15 days of continuous dosing) for twice-daily dosing cohorts
Supplementary Figure S1 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Authors: Weekes Colin D. , Von Hoff Daniel D. , Adjei Alex A. , Leffingwell Diane P. , Eckhardt S. Gail , Gore Lia , Lewis Karl D. , Weiss Glen J. , Ramanathan Ramesh K. , Dy Grace K. , Ma Wen W. , Sheedy Beth , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Dubowy Ronald L. , Jeffers Michael , Rajagopalan Prabhu , Clendeninn Neil J.
Published: April 2023

Treatment schema
Supplementary Figure Legend from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Authors: Weekes Colin D. , Von Hoff Daniel D. , Adjei Alex A. , Leffingwell Diane P. , Eckhardt S. Gail , Gore Lia , Lewis Karl D. , Weiss Glen J. , Ramanathan Ramesh K. , Dy Grace K. , Ma Wen W. , Sheedy Beth , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Dubowy Ronald L. , Jeffers Michael , Rajagopalan Prabhu , Clendeninn Neil J.
Published: April 2023

Legend for supplementary figure
Supplementary Table 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Authors: Cumberbatch Marie , Tang Ximing , Beran Garry , Eckersley Sonia , Wang Xin , Ellston Rebecca P.A. , Dearden Simon , Cosulich Sabina , Smith Paul D. , Behrens Carmen , Kim Edward S. , Su Xinying , Fan Shuqiong , Gray Neil , Blowers David P. , Wistuba Ignacio I. , Womack Chris
Published: April 2023

PDF file - 57K, Clinicopathological features of TMA Set 1.
Supplementary Materials and Methods, Tables 1 - 2 from Imaging the Norepinephrine Transporter in Neuroblastoma: A Comparison of [18F]-MFBG and 123I-MIBG
Authors: Zhang Hanwen , Huang Ruimin , Cheung Nai-Kong V. , Guo Hongfen , Zanzonico Pat B. , Thaler Howard T. , Lewis Jason S. , Blasberg Ronald G.
Published: April 2023

PDF file - 85KB, Table S1. Biodistribution of 18F-MFBG in neuroblastoma xenografts. Table S2. Biodistribution of 123I-MIBG in neuroblastoma xenografts.